Cosciens Biopharma Files June 2025 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1113423
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, corporate-update
TL;DR
Cosciens Biopharma (formerly Aeterna Zentaris) filed its June 6-K, standard corporate update.
AI Summary
Cosciens Biopharma Inc. filed a Form 6-K on June 30, 2025, reporting for the month of June 2025. The company, formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc., is a foreign private issuer. Its principal executive office is located in Toronto, Ontario, Canada.
Why It Matters
This filing provides routine updates for Cosciens Biopharma Inc., a biopharmaceutical company, which is important for investors tracking its regulatory compliance and corporate activities.
Risk Assessment
Risk Level: low — This is a routine filing and does not appear to contain significant new financial or operational information that would immediately impact the company's risk profile.
Key Numbers
- 001-38064 — SEC File Number (Identifies the company's registration with the SEC.)
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- AETERNA LABORATORIES INC (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- 20250630 (date) — Filing date and period of report
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have filed or are required to file with a stock exchange.
When was this specific Form 6-K filed and what period does it cover?
This Form 6-K was filed on June 30, 2025, and it reports for the month of June 2025.
What were the previous names of COSCIENS Biopharma Inc.?
The company was formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc.
Where is the principal executive office of COSCIENS Biopharma Inc. located?
The principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Does Cosciens Biopharma Inc. file annual reports under Form 20-F or 40-F?
Cosciens Biopharma Inc. indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).